Comparative Pharmacology
Head-to-head clinical analysis: IDVYNSO versus TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IDVYNSO versus TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE.
IDVYNSO vs TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IDVYNSO is a selective dopamine D3 receptor antagonist, which modulates dopaminergic neurotransmission in the mesolimbic pathway.
Trifluridine is a thymidine-based nucleoside analog that incorporates into DNA, interfering with DNA synthesis and function. Tipiracil hydrochloride inhibits thymidine phosphorylase, preventing trifluridine degradation and increasing its systemic exposure.
5 mg/kg IV once daily for 14 days; then 2.5 mg/kg IV once daily for 14 days.
35 mg/m² orally twice daily on days 1-5 and 8-12 of each 28-day cycle. Maximum dose: 80 mg per dose.
None Documented
None Documented
Terminal elimination half-life is 12–18 hours, supporting twice-daily dosing in patients with normal renal function.
The terminal elimination half-life of trifluridine is approximately 1.4 to 2.1 hours. For tipiracil, the half-life is about 2.1 to 3.3 hours. The short half-lives necessitate twice-daily dosing to maintain therapeutic concentrations.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%, with the remainder metabolized.
Trifluridine is primarily eliminated via metabolism and renal excretion. Approximately 29% of the trifluride dose is recovered in urine as trifluridine and its metabolites, with less than 3% as unchanged drug. Fecal excretion accounts for about 38% of the dose, mainly as metabolites. Tipiracil is predominantly excreted renally (about 55% as unchanged drug and metabolites) and fecally (about 19%).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent